Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study

NCT06398977 is registered in ClinicalTrials.gov with Sichuan Academy of Medical Sciences as lead sponsor.

NCT NCT06398977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06398977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dapagliflozin Delays the Loss of Residual Renal Function in Patients Undergoing Peritoneal Dialysis: A Single-Center Randomized Open-Label Study
Lead sponsor
Sichuan Academy of Medical Sciences
Phase
Not applicable
Overall status
Recruiting
Start date
March 11, 2024
Completion date
December 31, 2026
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal dialysis complication, renal function aggravated, sodium-glucose co-transporter-2 inhibitors